2005
Selling Safety—Lessons From Muraglitazar
Search citation statements
Paper Sections
Select...
15
2
1
0
Citation Types
0
18
0
0
Year Published
2005
2022
Publication Types
Select...
18
Relationship
0
18
Authors
Journals
Cited by 18 publications
(18 citation statements)
References 5 publications
0
18
0
0
“…Lastly, the strength of several associations was limited since some analyses were restricted by the number of incident events. Therefore, we used composite variables to increase the statistical power of our analyses 48 …”
Section: Discussionmentioning
confidence: 99%
“…Lastly, the strength of several associations was limited since some analyses were restricted by the number of incident events. Therefore, we used composite variables to increase the statistical power of our analyses 48 …”
Section: Discussionmentioning
confidence: 99%
“…In particular, readers need information on deaths, and on harms that can be lethal, such as thromboses causes by COX-2 inhibitors. In the drug literature, there is plenty of evidence of flawed research [34][35][36][37][38][39][40][41][42][43], ghost-written articles [24,25,[44][45][46][47], intimidation of researchers [44,45,[48][49][50][51][52][53][54][55][56] and misleading and false statements in research papers and marketing [24,[44][45][46][47][57][58][59][60][61][62][63][64][65].…”
Section: Discussionmentioning
confidence: 99%
“…In 2005, an FDA advisory committee recommended approval of an antidiabetes drug, muraglitazar, but independent researchers who analyzed the submitted trial data found that the original analyses supporting the FDA application were flawed, and that the drug was harmful [44,45]. …”
Section: Non-transparent Data On Lethal Harmsmentioning
confidence: 99%
